In this context, our in vivo experiments have demonstrated that targeting the CMA translocase enzyme LAMP2A inhibits the degradation of STING and TBK1, enhancing the infiltration of IFNγ+CD8+ T cells and thus improving the "cold" tumor state. Here, CD8A is linked to neoplasm.